Immuno-Oncology Assays and Inflammation Platform

At NUVISAN, we have developed an immunoassay/inflammation platform offering state-of-the-art preclinical in vitro and in vivo models and the application of biomarkers with pharmacodynamic, predictive, and surveillance utility. This supports your immunology research and development projects in oncology, inflammation, cardiology, neurology, obesity, diabetes, women’s health, and metabolic disorders.

NUVISAN’s inflammation/immunology technology platform has been developed to support functional cell-based assays and phenotypic profiling. It utilizes

For immuno-oncology and inflammation projects, we offer customized functional cell-based assays, such as:

  • human and mouse whole blood, T-cells, neutrophils, and monocytes
  • cytokine/chemokine profiling
  • differentiation assays (e.g., myeloid or plasmacytoid DCs, TH17 cells)
  • migration assays
  • in vitro fibroblast to myofibroblast transition
  • ex vivo re-stimulation assay (e.g., mediastinal lymph nodes [MLNs] with house dust mite [HDM])
  • immune-mediated tumor killing assays
    • Natural killer (NK) cell tumor killing assays
    • Cytotoxic T cell mediated tumor killing assays (2D and 3D)
  • immune cell infiltration/immune cell phenotyping.
  • spatial profiling of tumor-infiltrating immune cells
  • single and multicolor immunofluorescence (mIF) staining of intertumoral immune cell populations

T-cell infiltration in human NSCLC